HELIOS-B: Health benefits of vutrisiran for ATTR-CM may increase over time

Vutrisiran decreased the risk of all-cause and cardiovascular mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Moreover, new data from the HELIOS-B study suggest that the beneficial effects of vutrisiran may increase over time. In an updated data cut of the HELIOS-B trial (NCT04153149), Prof. Marianna Fontana (University College London, UK) specifically looked at all-cause and cardiovascular mortality at 42 months of follow-up [1]. The trial had randomised patients with ATTR-CM 1:1 to vutrisiran, a subcutaneously administered RNA interference therapeutic agent blocking the production of hepatic transthyretin, or placebo. After 36 months, participants could enter the open-label extension study of HELIOS-B. “At the time of the primary analysis, we had 42-month data from 42.4% of the ongoing participants [2],” explained Prof. Fontana. “Now, we have 42-month data from 96.3% o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 July 202521 July 2025